Dry eye disease Concentration of epitheliotrophic growth factors in PRP and AS Efficacy in treatment of DED of PRP and AS Stability of epitheliotrophic growth factors in PRP and AS epitheliotrophic growth factor autologous serum platelet-
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: The patients will be included to the study, when they meet all of the criteria Dry Eye Disease Diagnostic Test Battery: (modified from TFOS DEWS II; Diagnostic Methodology report) OSDI (Ocular Surface Disease Index) ≥ 13 Diagnostic Testing (Homeostasis Markers) Fluorescein Breakup Time 5 corneal spots or - > 9 conjunctival spots or - Lid margin (≥ 2mm length & ≥ 25% width)
Exclusion criteria
Exclusion criteria: Taking immunosuppressive drugs AIDs patients or other immunodeficiency conditions Having serious systemic underlying diseases Pregnant women Unequal severity of dry eye disease between two eyes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Concentration of epitheliotrophic growth factors in Platelet-Rich Plasma and Autologous Serum At the time of intervention Enzyme-linked immunosorbent assay (ELISA) according to the manufacturers’ instruction | — |
Secondary
| Measure | Time frame |
|---|---|
| The efficacy of PRP and AS in DED 1 month Dry eye ocular symptoms (OSDI score and Dry Eye Questionnaire, used in The Osaka Study16) and signs(,the stability of epitheliotrophic growth factors in PRP and AS Baselline, 1 month, 6 months enzyme-linked immunosorbent assay (ELISA) according to the manufacturers’ instruction at 1 week, 1 | — |
Contacts
Faculty of Medicine Siriraj Hospital, Mahidol University